Medication Comparison · Updated November 2026

Zepbound vs Wegovy: Which FDA-Approved Weight Loss GLP-1 Should You Choose?

Zepbound and Wegovy are the two best-known weekly injections with FDA approval for chronic weight management. (Saxenda, a daily liraglutide injection, is also approved for weight management.) They work differently, produce different amounts of weight loss, and cost different amounts. I have been on tirzepatide (the molecule in Zepbound) for over a year and track my results with DEXA scans. This is the comparison I wish I had when I was deciding.

TL;DR

• Zepbound (tirzepatide) produced 20.2% weight loss vs Wegovy’s 13.7% in the direct head-to-head SURMOUNT-5 trial. That is roughly 47% more weight loss.
• Wegovy has cardiovascular outcome data in people without diabetes from the SELECT trial, which showed a 20% lower risk of cardiovascular death, heart attack, or stroke. Tirzepatide’s outcome trial so far (SURPASS-CVOT) was in people with type 2 diabetes, so it is not a direct match.
• Self-pay prices as of Nov 4, 2026: Zepbound costs $299 to $449/mo through LillyDirect. Wegovy pens cost $349/mo after a $199 intro offer, and Wegovy pills start at $149/mo through NovoCare. Wegovy’s list price is $1,349.02 per package.
• Wegovy has been on the market longer (approved 2021 vs 2023 for Zepbound). Coverage depends on your plan, so check both.
• Wegovy is now available as a daily pill (added to the Wegovy label in December 2025). Zepbound is injection-only.

Quick Comparison Table

Active Ingredient and Mechanism

Zepbound and Wegovy are fundamentally different drugs. They share the GLP-1 pathway, but that is where the similarity ends.

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. It activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Think of it as two separate appetite and metabolism signals firing at once. The GIP component appears to enhance fat metabolism beyond what GLP-1 alone can do.

Wegovy contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It targets one hormone receptor (GLP-1), which slows gastric emptying, reduces hunger signals to the brain, and improves insulin sensitivity.

Both injections are given once weekly, and Wegovy also comes as a daily pill. The key difference is that tirzepatide’s dual mechanism is widely believed to explain its greater weight loss results. For more on how these molecules compare, see our full four-way comparison.

FDA Status

Both Zepbound and Wegovy are FDA-approved for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition. Each has extra indications. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label). Wegovy is also approved to lower the risk of major cardiovascular events in adults with heart disease and obesity or overweight, and for noncirrhotic MASH with moderate to advanced liver fibrosis (Wegovy label).

• Wegovy was approved in June 2021. It has been on the market longer, which matters for insurance formulary placement.
• Zepbound was approved in November 2023.

Both are on-label for weight loss. Neither requires a diabetes diagnosis. Insurance coverage varies by plan (more on that below).

Weight Loss Data: SURMOUNT-5 Head-to-Head

This is the comparison that matters most, because we have a direct head-to-head trial.

The SURMOUNT-5 trial was an open-label trial that randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. The results:

• Tirzepatide group: 20.2% body weight loss
• Semaglutide group: 13.7% body weight loss

For a 250-pound person, that translates to roughly 50.5 pounds lost on Zepbound versus 34.3 pounds on Wegovy. That is a 16-pound difference between the two groups on average.

The tirzepatide group was also more likely to reach every weight loss threshold the trial tracked. In the ClinicalTrials.gov results posting, 36.5% of tirzepatide participants with evaluable data lost at least 25% of their body weight, compared with 18.6% on semaglutide.

I have been tracking my own DEXA scans on tirzepatide, and the fat loss has been consistent month over month. The data from SURMOUNT-5 matches what I have seen in practice. Tirzepatide is the stronger drug for pure weight loss. That said, Wegovy’s 13.7% is still substantial. Losing 13-14% of your body weight is life-changing for most people.

Dosing Schedule

Both are weekly injections, but the dose ranges are different.

Zepbound (tirzepatide):

• Starting dose: 2.5 mg/week for 4 weeks
• Then: 5 mg, with increases in 2.5 mg steps after at least 4 weeks on each dose
• Maintenance: 5 mg, 10 mg, or 15 mg for weight loss
• Max dose: 15 mg/week

Wegovy (semaglutide) injectable:

• Starting dose: 0.25 mg/week for 4 weeks
• Then: 0.5 mg, 1 mg, 1.7 mg (4 weeks each), then a 1.7 mg or 2.4 mg maintenance dose
• Max dose: 7.2 mg/week (Wegovy HD), only for people who tolerate 2.4 mg for at least 4 weeks and need more weight loss

Wegovy oral pill (approved December 2025):

• Taken once daily on an empty stomach with up to 4 ounces of water, then wait 30 minutes before eating
• Steps up from 1.5 mg to 4 mg to 9 mg, then a 25 mg maintenance dose
• No injection required

These schedules come from the Zepbound label and the Wegovy label. Your prescriber may hold you at a dose longer if side effects are a problem. Follow your prescriber’s plan rather than moving up on your own.

The Wegovy pill is a real differentiator. If needles are a barrier for you, oral semaglutide is now an option. We wrote a full breakdown of the Wegovy pill vs injection if you want the details on how they compare.

Side Effects

The side effect profiles overlap significantly. Both drugs cause GI issues, especially during dose escalation.

Most common side effects for both:

• Nausea (most reported, usually peaks 1-2 weeks after each dose increase)
• Diarrhea
• Constipation
• Vomiting
• Decreased appetite
• Injection site reactions

From SURMOUNT-5: GI side effects were the most common adverse events in both groups, and most were mild to moderate and happened during dose increases. In the ClinicalTrials.gov results posting, 6 people in each group left the trial because of an adverse event.

From my own experience on tirzepatide, the nausea was most noticeable during the first week at each new dose. By week 2-3, it settled down. Eating smaller meals and avoiding greasy food helped the most. For a full month-by-month breakdown of what to expect, see our GLP-1 side effects guide.

Serious side effects (rare, both drugs): Pancreatitis, gallbladder problems, kidney injury from dehydration, and thyroid C-cell tumor warnings (from rodent studies). Both carry a boxed warning about medullary thyroid carcinoma risk and are contraindicated if you have a personal or family history of MTC or MEN 2. Neither should be used during pregnancy.

Cardiovascular Data

This is where Wegovy has an edge that Zepbound cannot match yet.

The SELECT trial studied semaglutide 2.4 mg (the standard Wegovy dose) in 17,604 adults with established cardiovascular disease, a BMI of 27 or higher, and no diabetes. The result: a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke) over a mean follow-up of 39.8 months.

Tirzepatide’s cardiovascular outcome trial so far, SURPASS-CVOT, compared it with dulaglutide in adults with type 2 diabetes and heart disease. It was not a placebo-controlled trial in people with obesity alone, so it does not answer the same question SELECT did.

If you have existing heart disease or significant cardiovascular risk factors, the SELECT data gives Wegovy a meaningful advantage. This is worth discussing with your doctor.

Cost Comparison

Prices above are from LillyDirect and NovoCare as of Nov 4, 2026. At maintenance doses, Zepbound self-pay is $449/mo if you refill within 45 days ($499 to $699 if you do not), and a standard Wegovy pen is $349/mo.

If your insurance covers one drug and not the other, your out-of-pocket cost for the covered drug will usually be far lower than either self-pay price.

For a full breakdown of the cheapest ways to access both drugs, see our cheapest GLP-1 online guide.

Insurance Coverage

Commercial coverage varies by plan. Many employer plans still exclude weight-loss drugs. Wegovy’s cardiovascular and MASH indications and Zepbound’s sleep apnea indication can matter, because some plans cover those uses even when they exclude weight loss. Ask your plan which drug is on its formulary.

Medicare now has a weight-loss path. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027. Eligible Part D enrollees pay $50 a month for any form of Wegovy or the Zepbound KwikPen (not the single-dose pens or vials), with prior authorization. People prescribed these drugs for sleep apnea, type 2 diabetes, or MASH get them through their regular Part D plan instead. See our GLP-1 insurance coverage guide for tips on getting approved.

Choose Zepbound If…

• Maximum weight loss is your top priority. The SURMOUNT-5 data is clear: tirzepatide produces significantly more weight loss than semaglutide.
• You can access it affordably. Whether through insurance, LillyDirect self-pay, or the Medicare GLP-1 Bridge.
• You have tried semaglutide and plateaued. Some people switch from Wegovy to Zepbound and see renewed progress. The dual mechanism may work better for certain people.
• You are okay with injections. Zepbound is injection-only (no oral option).

Choose Wegovy If…

• You have heart disease. SELECT showed a 20% lower risk of cardiovascular death, heart attack, or stroke in people with established heart disease and overweight or obesity.
• Your insurance covers it but not Zepbound. A covered Wegovy prescription usually costs far less than Zepbound self-pay.
• You want the oral pill option. The Wegovy pill (approved December 2025) removes the needle barrier entirely. See our pill vs injection guide.
• You prefer a longer track record. Semaglutide was first approved in 2017 (the Wegovy label lists an initial U.S. approval of 2017), so more long-term real-world data exists.

Frequently Asked Questions

Can I switch from Wegovy to Zepbound (or vice versa)?

Yes. Switching between semaglutide and tirzepatide is common. Your provider will typically restart you at the lowest dose of the new medication and titrate up, because they work on different receptors. Do not try to dose-match between the two drugs on your own. Let your prescriber handle the transition.

Is Zepbound better than Wegovy for everyone?

No. Zepbound produces more average weight loss in clinical trials, but individual responses vary. Some people respond very well to semaglutide and see weight loss at or above the tirzepatide averages. Others respond better to tirzepatide. If cost, insurance, or cardiovascular health is a priority, Wegovy may be the better choice for your specific situation.

Does Medicare cover Zepbound or Wegovy?

For weight management, eligible Part D enrollees can use the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027. It costs $50 a month and covers all forms of Wegovy and the Zepbound KwikPen. Part D plans can also cover Zepbound for sleep apnea and Wegovy for cardiovascular risk reduction or MASH. If you have Medicare and type 2 diabetes, you may be able to get Mounjaro or Ozempic covered instead.

What about compounded versions?

Compounded tirzepatide and semaglutide are not FDA-approved. The FDA has removed both drugs from its shortage list, and the grace periods for routine compounded copies ended in 2025. Some telehealth companies still sell compounded versions, so ask any provider how its product is made and which pharmacy makes it. See our compounded vs brand-name guide for the full breakdown on safety, legality, and quality differences.

Which one has fewer side effects?

Both drugs cause nausea, diarrhea, vomiting, and constipation, mostly during dose increases. SURMOUNT-5 did not show a clear tolerability winner. Your own response matters more than trial averages, so tell your prescriber if side effects do not settle.

Last updated: November 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed the FDA labels for Zepbound and Wegovy, the SURMOUNT-5 and SELECT trial publications and the SURMOUNT-5 ClinicalTrials.gov results, the LillyDirect and NovoCare self-pay pages, the CMS Medicare GLP-1 Bridge page, and the FDA compounding policy page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.